Standard terminology and principles for vaccine delivery costs



Standard terminology and principles for vaccine delivery costs



Standard terminology and principles for vaccine delivery costs

ISBN 978-92-4-005247-5 (electronic version) ISBN 978-92-4-005248-2 (print version)

© World Health Organization 2022

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (http://www.wipo.int/amc/en/mediation/rules/).

Suggested citation. Standard terminology and principles for vaccine delivery costs. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.

Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see https://www.who.int/copyright.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Contents

| 1. Acknowledgements | iv |
|---|----|
| 2. Background | |
| 3. Objectives of the guidance for the immunization costing community | 2 |
| 4. Vaccination delivery cost analyses | 3 |
| 5. Review of existing guidance documents and costing tools | 7 |
| 5.1 Terminology and definitions of costs in workstreams | 7 |
| 5.2 Areas for clarification and harmonization | 8 |
| 6. Recommendations for costing terms by Working Group | 9 |
| 7. Recommendations for costing principles for the methodological approaches | 12 |
| Annexes | |
| Annex 1. Timeline for developing the standard terminology and principles for vaccine delivery costs | 16 |
| Annex 2. List of existing guidance and costing tools for vaccine delivery costing | 17 |
| Annex 3. Definition of costing terminology | 21 |
| Annex 4. Costing principles | 27 |
| Annex 5. Characteristics of costing workstreams | 32 |
| Annex 6. Areas for clarification and harmonization | 35 |

Acknowledgements

Working Group members:

Bill & Melinda Gates Foundation: Logan Brenzel

Centers for Disease Control and Prevention (CDC): Sarah Pallas

Harvard T.H. Chan School of Public Health: Stephen Resch, Christian Suharlim,

Stéphane Verguet

International Vaccine Institute: Vittal Mogasale

Levin & Morgan LLC: Ann Levin

London School of Hygiene & Tropical Medicine: Mark Jit

ThinkWell: Laura Boonstoppel

United Nations Children's Fund (UNICEF): Ulla Griffiths

World Health Organization (WHO): Xiao Xian Huang, Raymond Hutubessy,

Karene Hoi Ting Yeung

Other contributors and reviewers:

Centers for Disease Control and Prevention (CDC): Taiwo Abimbola, Anna Hidle, Timothy Brennan, Nelly Mejia, and Carlo Davila Payan

World Health Organization (WHO): Shuoning Huang (intern)

Background

This guidance was developed in response to a request from the World Health Organization (WHO) Immunization and Vaccines-related Implementation Research Advisory Committee (IVIR-AC). They requested that "guidance be developed for standardization of micro-costing and planning tools, on new vaccine introduction on where to obtain data, at what level it should be collected, how to conduct sampling, and methods used in vaccine delivery costing". In response to this request, an ad hoc Working Group was created to oversee the development of this guidance for WHO.

The Working Group identified that multiple efforts, either in process or completed, each partly addressed or are addressing the original IVIR-AC request on data collection, sampling, and methods to be used in vaccine delivery costing. Each of these efforts has different purposes. With this new information, in March 2019, IVIR-AC modified their request to instead review and document the various workstreams that are being conducted in immunization costing. In July 2019, the Working Group met to discuss the vaccine delivery costing work taking place through different organizations. They noted some differences in terminology and principles among the organizations. As a result, they agreed to develop this guidance to harmonize key terminology and clarify the scope of the various methods. Annex 1 shows a figure that illustrates the chronology of presentations to IVIR-AC on vaccine delivery costing and other meetings to develop the guidance.

The target audience for the guidance is the developers of costing tools or guidance, vaccine delivery cost researchers, and funders of costing tools, guidance and studies. The expectation is that the terminology and methods utilized in the future for developing new tools or guidance, undertaking delivery cost studies, interpreting findings on vaccine delivery costs, or reviewing studies/research/tools will be consistent with this guidance. It recognizes that retroactive changes to published costing tools and guidance documents that differ from the recommended terminology and methods may not be feasible. This guidance summarizes similarities and differences in data collection and sampling methods among costing approaches as well as gaps in guidance documents.

Weekly Epidemiological Record. 2018;93(24):345–356.

Objectives of the guidance for the immunization costing community

The objectives of the guidance are the following:

- to highlight and explain commonalities and differences across different costing approaches, tools, and guidelines;
- to highlight the objectives of different costing approaches, tools, and guidelines;
- to encourage improvement and innovation in methods and tools that are fit for purpose;
- to advance the immunization economics community of practice by committing to follow certain principles and common definitions (as detailed in Annex) that will make the collective costing work more easily interpretable and useful, while acknowledging that some deviations may occur due to limits to standardization of approaches with different objectives.

To achieve these objectives, the Working Group reviewed terminology, definitions, and principles of guidance documents and costing tools for vaccination delivery. Recommendations for costing principles and terminology were developed.

For the purpose of this document, the definition of vaccine delivery costing is the following: costs associated with delivering immunizations to target populations, exclusive of vaccine costs. Vaccine delivery costs can be disaggregated into financial and economic delivery costs (see cost definitions below).

Vaccination delivery cost analyses

Efforts to estimate the costs of immunization programmes, strategies, and new vaccine introductions have utilized various methodological approaches as described below. The approach selected is usually based on the purpose of the analysis and the type of information that decision-makers need. The Working Group qualitatively characterized workstreams based on their knowledge of groups currently working in the field following a 2019 International Health Economics Association pre-congress session on vaccine economics in Basel, Switzerland. These characterizations were intended to help elucidate where and why differences in definitions and methods were occurring and were not derived from any prior framework.

Major workstreams on costing of vaccine delivery and immunization programme costing identified by the Working Group are the following:



Retrospective routine immunization (multiple vaccines) cross-sectional costing

The first workstream is focused on estimating retrospective (i.e., already incurred) routine immunization, cross-sectional costs of service delivery units at a single point in time, typically using a full costing approach. This method provides a range of unit costs (cost per dose, cost per person, cost per fully immunized person [FIP]) by facility, district, and higher levels in the health system for total routine immunization delivery costs. Costs are economic and/or financial costs. It includes, for example, the work conducted in the Expanded Programme on Immunization Costing (EPIC) studies (see www.immunizationeconomics.org) and other work by groups, such as the Curatio Foundation, Harvard School of Public Health, Johns Hopkins University, PAHO, PATH, ThinkWell, United Nations Children's Fund (UNICEF), and Wits University (see Annex 2 for details). The purposes are to determine delivery costs of the entire routine immunization programme as it currently operates for benchmarking and/or to explain variation in facility costs and unit costs (e.g., cost determinants, efficiency).

2

Retrospective single-vaccine costing

The second approach is to estimate retrospective costs for a specific vaccine, typically using incremental costing. Retrospective estimation of incremental vaccine-specific campaign and new vaccine introduction costs differs from full costing of routine immunization in requiring some implicit or explicit estimation of counterfactual resource use in the absence of that campaign or vaccine introduction. This is often done through data collection at a single point in time (post-campaign or post-introduction) with reference to documents and recall by key informants to estimate which resource use was specifically incremental. Examples of such studies are being applied by groups such as Centers for Disease Control and Prevention (CDC), Harvard School of Public Health (EPIC studies), International Vaccine Institute (IVI), ThinkWell, UNICEF and WHO. Costing tools used to estimate retrospective costs include, but are not limited to (see Annexes for websites for these tools):

- the IVI/WHO CHOLTOOL
- the WHO Cervical Cancer Prevention and Control Costing Tool (C4P)
- the WHO Seasonal Influenza Immunization Costing Tool (SIICT)
- the WHO/IVI Typhoid Vaccine Costing Tool (TCVCT)
- the PATH Malaria Vaccine Immunization Costing Tool (MVICT)
- the PAHO ProVac/COSTVAC

Incremental costing of a specific vaccine, whether delivered through campaign or routine immunization, differs substantially from full costing of routine immunization because it involves not only estimating the proportion of shared health system resources used for immunization, but also the extra step of allocation by vaccine. In particular, campaign delivery may differ in frequency, administrative levels (sometimes sub-national rather than national), whether these are preventive or in response to outbreaks (e.g., oral cholera vaccine [OCV] provision), for catch-up, and whether these involve populations other than young children and pregnant women, such as health workers, adolescent girls, or all ages over one year for OCV. When conducted for a campaign, the purpose of these cost analyses may be for retrospective evaluation of campaign costs (including as an input to cost-effectiveness analyses), explaining variation in costs by strategy and venue, and cost projections for planning and decision-making on conducting campaigns. When estimating

retrospective costs of new vaccine introduction, whether via campaign or routine immunization, the purpose of these analyses may be to inform country planners and decision makers, and global funders on the costs of introduction and recurrent costs over time. Both financial and economic costs are estimated.

3

Projection of new vaccine introduction costs

The third approach is estimation of new vaccine introduction costs through the projection of the price and quantity of ingredients (e.g., time, equipment, vaccines, etc.) needed for vaccine introduction, typically using incremental costing for a specific period, e.g., one or five years. The prices and quantities of ingredients are obtained through interviews with programme managers and facility visits to obtain current information on for instance personnel time, supplies, and equipment. The projections are often conducted with the same costing tools as found in the second workstream: C4P, SIICT, TCVCT, CHOLTOOL, and MVICT. Examples of such studies have been funded by Bill & Melinda Gates Foundation (BMGF) through CDC, EPIC, IVI, PATH, UNICEF and WHO. Another tool, the Vaccine Technology Impact Assessment Tool (VTIA), is used to compare the commodity and system costs for a new vaccine technology (e.g., temperature stability vaccines) with the current one. The purpose of these cost projections is for planning and decision-making on new vaccines during the introduction period. Costs are shown for both financial and economic costs and include cost per dose and FIP as well as total annual costs.


4

Projection of national immunization programme costs

The fourth workstream is immunization programme cost projection (e.g., comprehensive multi-year plan [cMYP], tool for estimating costs of implementing a second year of life healthy child visit (2YL), OneHealth tool) where the activities of a national programme and related cost is approximated for a baseline year and then the costs of future years are projected. This is a type of costing for strategic planning to assist in budgeting, resource planning, and mobilization over a strategic period. These projections estimate undepreciated financial costs; also, both annual and three to five-year costs are estimated.

Figure 1 shows the four workstreams, their lead agencies/funders, and associated guidance documents/tools.

Figure 1. Major current workstreams in vaccine delivery costing identified by Working Group



2YL: Tool for estimating costs of implementing a second year of life healthy child visit; BMGF: Bill & Melinda Gates Foundation; C4P: Cervical Cancer Prevention and Control Costing Tool; CDC: United States Centers for Disease Control and Prevention; CHOLTOOL: Oral Cholera Vaccine Costing Tool; cMYP: comprehensive multi-year plan; EPIC: Expanded Programme on Immunization Costing; ICAN: Immunization Costing Action Network; IVI: International Vaccine Institute; MVICT: Malaria Vaccine Immunization Costing Tool; SIICT: Seasonal Influenza Immunization Costing Tool; TCVCT: Typhoid Conjugate Vaccine Costing Tool; UN: United Nations; UNICEF: United Nations Children's Fund; VTIA: Vaccine Technology Impact Assessment Tool; WHO: World Health Organization.

Review of existing guidance documents and costing tools

Annex Table A2a and Table A2b show the eleven existing guidance documents and eleven tools for costing vaccine delivery and immunization programmes. These were identified by the Working Group as of July 2020. Note that this list is based on Working Group members' personal knowledge and prior reference to them in conducting immunization delivery costing and may not be exhaustive. A few of these guidance documents and tools are for costing health services more generally, such as the OneHealth Tool and the Community Health Planning and Costing Tool (CHPCT).

The review showed that some gaps in costing guidance for the workstreams exist on how to consider slackness of resources, estimation of shared resources for the interventions and specific vaccines, and sampling and respondent selection, particularly for the cost projections for vaccine introduction.

Terminology and definitions of costs in workstreams

Annex **Table A3** shows definitions of costing terminology found in the guidance documents. The guidance documents have similar definitions of financial and economic costs, and recurrent and capital costs, but vary in the level of details of the definitions. Most guidance documents do not describe in detail issues of interactions¹ between terminology, perspective, financial vs. economic costs², and how incremental costing affects financial vs. economic costing³. For example, incremental costs for financial costs will differ depending on the perspective of the

¹ An Interaction is the action or influence of things on one another (merriam-webster.com).

² Financial costs only include resources paid for by the "buyer" or "provider" and will therefore be affected by the perspective chosen for the analysis.

³ The definitions are not clear about whether resources that already exist before the intervention (e.g., cold chain equipment) should be included in economic costs and how excess capacity should affect these (e.g., whether the costs should only be included if there is no slack capacity to absorb the new intervention resource requirements).

analysis; if the perspective is of the public health provider, resources donated by external entities will not be included.

Annex **Table A4** compares the costing principles in the guidance documents with the Global Health Cost Consortium (GHCC) Principles and Methods Reporting Checklist¹. Guidance documents vary in the extent to which costing principles are discussed. Most guidance documents refer to study purpose, classification of costs, the time horizon of data collection, presentation of costing methods, and depreciation of capital costs. Other principles such as describing the timing of data collection and listing sources for price data are only discussed by one or two of the guidance documents (see discussion in Annex).

Annex Table A5a compares the level of data collection, activities/cost categories, perspective, and definitions of cost terms and perspective among the workstreams and shows the variations among these. Annex Table A5b shows differences in data sources, sampling, and characterization of uncertainty by workstream.

Areas for clarification and harmonization

Based on the review, some specific areas that need further clarification and harmonization have been identified in terms of data collection, sampling, and characterization of uncertainty. These are shown in **Annex 6**.

Reference case for estimating the costs of global health services and interventions. Washington: Global Health Cost Consortium; 2017 (https://ghcosting.org/pages/standards/reference_case, accessed 28 April 2022).

Recommendations for costing terms by Working Group

The Working Group reviewed costing term definitions in the existing guidance documents. Based on the definitions shown in Annex **Table A3**, they developed recommendations for costing terms to be used in estimates of vaccine delivery cost.

The following definitions of costing terms are recommended by the Working Group:

1. Vaccine delivery costs

Costs associated with delivering immunization programmes to target populations, exclusive of vaccine costs.

2. Vaccine cost

At a minimum includes the cost of the vaccine and diluent (if applicable); the analysis should include accounting for wastage rates; the analyst should specify whether this also includes injection supplies (syringes), international shipment, insurance, and customs/duties.

3. Financial cost

Monetary outlays, with straight-line depreciation for capital goods; does not include opportunity costs for use of resources or donated goods and services from sources other than the payer(s) defined in the analysis. Definition is dependent on perspective since monetary outlays are specific to the payer(s) defined in the analysis.

4. Economic cost

The value of all resources utilized, regardless of the source of financing. Includes opportunity costs for use of existing resources and any donated goods or services from any source. Capital costs are annualized and discounted.

5. Undepreciated financial cost

Financial costs without depreciation of capital costs. (Note: such costs have been termed "initial investment" in some costing tools and referred to as fiscal costs in previous analyses.)

6. Recurrent cost

Value of resources that last less than one year. Start-up activity costs may include recurrent costs.

7. Capital cost

Value of resources lasting more than one year such as equipment, buildings, and trainings. Start-up activity costs may include capital costs.

8. Incremental cost

Cost of adding a new service/intervention or a package of services/interventions over and above an existing programme; inclusion of existing resources will depend on assumptions made about excess capacity (i.e., whether resources are underemployed; if there are no slack resources (e.g., all personnel time is fully allocated before the addition of the new service/intervention), then their use for the new service or intervention incurs an opportunity cost that should be included – either by measurement or assumption).

9. Full cost

Baseline cost as well as the additional cost of the new intervention, including vaccine cost.

10. Cost projection

Estimation of future costs of both recurrent and capital inputs.

11. Prospective data collection

Direct observation of resource use during intervention implementation, i.e., data are collected concurrently with intervention implementation.

12. Retrospective data collection

Data collection after resource use is completed.

13. Start-up cost

Cost of initial one-time programmatic activities. Examples may include initial micro-planning, initial training activities, and initial sensitization/social mobilization/information, education and communication (IEC); does not include routine or repeated programmatic activities such as refresher training or annual microplanning. Start-up activities may include both recurrent and capital costs; they are defined by the non-repeating nature of the activity, not the type of input.

14. Micro-costing

Focuses on granular accounting of input prices and quantities; disaggregates costs of particular output into specific goods and services consumed.

15. Bottom-up costing

Measures input quantities at the client (e.g., per vaccination administered) or activity level.

16. Top-down costing

Divides overall programme cost or expenditures, often including those at administrative levels above service level, by number of outputs to calculate unit cost.

17. Perspective

The point of view considered for costs (and benefits, if included) in a costing study, by whom the costs were incurred. Payers are the disbursing agents for a good or service, and may differ from the original source of funding. A provider perspective includes costs incurred by health service providers (can be limited to the government), a payer perspective includes costs to the payer(s), such as government or an external partner, while the societal perspective includes all costs incurred by providers as well as clients.

18. Shared cost

Shared resources that are not used only for immunization, but also for other productive activities.

Recommendations for costing principles for the methodological approaches

The Working Group reviewed costing principles in the various guidance documents and compared these to the GHCC reference case since this document has the most comprehensive set of principles for health service costing. Based on a review of similarities and differences among the guidance documents, they developed recommendations for the costing principles to be used in future costing studies.

The recommended costing principles include the following.

- **1.** Definitions of terms used in studies of vaccine delivery costing should conform closely to the recommended definitions in this guidance.
- 2. The study scope in terms of its purpose, audience, target population, time horizon, and service/output should be clearly stated. It should also state whether data collection will be prospective or retrospective, and whether the analysis will be retrospective or a cost projection.
- **3.** The perspective of the cost estimation should be stated and justified.
- 4. Types of costs to be generated should be clearly defined in terms of start-up/introduction or non-start-up/introduction (sometimes called operating costs), recurrent and capital, undepreciated financial, financial or economic, and incremental or full. Capital costs should be appropriately annualized and depreciated for financial and economic costs and the discount rate justified.
- **5.** The scope of the inputs to be estimated should be defined, justified and if needed referenced. For example, do the costs include national and sub-national costs or only facility-level service delivery costs? Are non-immunization costs included?

- **6.** The "units" in the unit costs for strategies, services and interventions should be defined, e.g., cost per dose administered.
- **7.** If incremental costing is conducted, any assumptions made regarding existing health system capacity should be described (see GHCC reference case, p. 64).
- **8.** The selection of the data sources, including any adjustments to price data (e.g., inflation or currency conversion) should be described and referenced.
- **9.** The methods for estimating the quantity of inputs should be described whether top-down or bottom-up, methods of allocation, use of shadow prices and the opportunity cost of time, and methods for excluding research and evaluation costs.
- **10.** Costs should be mapped and reported as either inputs or activities:
 - resource inputs include, for example, personnel time, vaccines, injection and safety supplies, vehicles, fuel, per diem and travel allowances, cold chain equipment, stationery, laboratory equipment, and buildings;
 - programme activities include, for example, vaccine procurement, service delivery, training, micro-planning, social mobilization and advocacy and communication, monitoring and evaluation, surveillance, adverse event following immunization, monitoring, and supervision.
- Nome boundaries around costs included in the analysis may be employed to keep the costing scope feasible and will depend on the purpose of the costing study, with the rationale for any exclusions provided; use discretion about including one-time costs that are unique or unlikely to be replicated or transferable across settings (for example, new vaccine launches with the President). Clarify definition and threshold for small costs that have expected small (e.g., < US\$25) contribution to total costs in aggregate across all sampled units, such as the use of existing office supplies by health facility staff.
- 12. The sampling strategy employed should aim for internal and external validity of the data. Sampling strategy should be stated, described, and justified, depending on the workstream and costing objectives. Sampling of different service delivery units is desirable as it provides a more representative picture of costs and highlights cost variation and cost drivers for a strategy or vaccine.


¹ Internal validity refers to the extent of systematic bias in an estimate while external validity is the extent to which the cost estimate can be directly applied to other programmatic setting. (GHCC, p. A15–A16).

- **13.** Variation in the cost of the intervention by site/organization, sub-population, or by other drivers of heterogeneity should be explored and reported for retrospective analyses when possible.
- **14.** The uncertainty around the cost estimates should be appropriately characterized when feasible, e.g., sensitivity analyses, ranges of results for different input parameter scenarios for cost projections, mean and standard deviation for non-representative samples with multiple units, and confidence intervals or credible intervals for retrospective analyses.
- **15.** Inclusion and exclusion criteria: "stopping rules" should be defined, explaining which costs are included and the respective rationale.
- **16.** Cost estimates should be communicated clearly and transparently to enable decision-makers to interpret and use the results relevant to the original policy and/or programmatic question.

¹ A "stopping rule" defines and explains which costs are included, and how the line is drawn between inclusions and exclusions. (GHCC reference case, p. B–2)

Annexes for the standard terminology and principles for vaccine delivery costs

Annex 1. Timeline for developing the standard terminology and principles for vaccine delivery costs



IVIR-AC: Immunization and Vaccine-related Implementation Research Advisory Committee; WG: Working Group.

Annex 2.

List of existing guidance and costing tools for vaccine delivery costing

Table A2a presents the list of guidance documents with their year of publication, target interventions, and purpose as identified by the Working Group. One document is a training manual for costing primary health care services, one document is a reference case for costing global health

care interventions, and the rest are specifically about costing of vaccine delivery. Note that some publications such the textbook on vaccine economics are forthcoming and are not shown in the table.

Table A2a. List of guidelines by publication year, target interventions, and purposes

| Developer | Guidelines | Publication years | Target Interventions | Purposes | Link |
|-----------|---|-------------------|--|--|---|
| WHO | Cost analysis in primary health care: a training manual for programme managers | 1994 | Primary health care | Assist health programme managers to cost their services for planning and evaluating efficiency | https://apps.who.int/iris/handle/10665/40030 |
| WHO | Guidelines for estimating costs of introducing new vaccines into the national immunization system | 2002 | New vaccine programmes | Assist countries in planning for introduction of new vaccines | https://apps.who.int/iris/handle/10665/67342 |
| | WHO guide for standardization of | 2008 (ed. I) | Existing and new | Methodology for cost and cost-effectiveness | https://apps.who.int/iris/bitstream/handle/10665/69981/ WHO_IVB_08.14_eng.pdf |
| WHO | economic evaluations of immunization programmes | 2019 (ed. II) | vaccine programmes | analyses of vaccines | https://apps.who.int/iris/bitstream/handle/10665/329389/ WHO-IVB-19.10-eng.pdf |
| | and financing analyses of routine immunization and now vaccing | | Methods for data collection for routine programmes and new vaccine introduction (including delivery costs) and financial flows | http://static1.squarespace.com/ static/556deb8ee4b08a534b8360e7/t/55970258e4b03cf94 2da51ac/1435959896232/WEBSITE_Common+Approach.pdf | |
| EPIC | How to cost immunization programs – a practical guide on primary data collection and analysis | 2020 | vaccine programmes | Practical guidance on how to conduct a facility-based exercise on immunization programme costs, including sampling and analytical techniques | https://msh.org/wp-content/uploads/2021/06/howtocost_digital_12.24.20.pdf |

| Developer | Guidelines | Publication years | Target Interventions | Purposes | Link |
|-----------|--|-------------------|---|--|--|
| GHCC | Reference case for estimating the costs of global health services and interventions | 2017 | Health interventions in general | Improve quality of cost estimates | https://ghcosting.org/pages/standards/reference_case |
| WHO | Immunization costing & financing: a tool and user guide for comprehensive multi-year planning (cMYP) | 2006 | Immunization programmes | To facilitate costing and finance estimation of a cMYP | https://apps.who.int/iris/handle/10665/69625 |
| ICAN | Methodology note for systematic review, cost catalogue, and analytics How to conduct the cost of a campaign: methodo-logical guidance to be completed in 2020 ^a | 2019 | Immunization delivery costs | Designed for users of data, including national and sub-national planners and policymakers, researchers, and international partners supporting country immunization and health system policy, planning, and financing | https://immunizationeconomics.org/ican-idcc-methodology |
| IVI/WHO | CHOLTOOL user guide | 2015 | Cholera-specific vaccination programmes, including campaigns | Instructions for users of costing tools | https://www.tandfonline.com/doi/ful l/10.1080/21645515.2020.1747930 |
| WHO | C4P tool: HPV vaccination module user guide | 2012-2019 | HPV vaccination programmes | Instructions for users of costing tool | TBD |
| WHO | Flutool plus (SIICT): introduction planning and costing | 2017 | Seasonal influenza vaccination programmes, including campaigns | Instructions for users of costing tool | https://www.who.int/publications/i/item/flutool-plus |

^a This guide was published after the finalization of this guidance and is available online: https://static1.squarespace.com/static/556deb8ee4b08a534b8360e7/t/61571c3d5bb7bb6a-d93e720f/1633098822790/How+to+cost+an+immunization+campaign_29Sept.pdf.

C4P: Cervical Cancer Prevention and Control Costing Tool; CHOLTOOL: Oral Cholera Vaccine Costing Tool; cMYP: comprehensive multi-year plan; EPIC: Expanded Programme on Immunization Costing; GHCC: Global Health Cost Consortium; HPV: human papillomavirus; ICAN: Immunization Costing Action Network; IVI: International Vaccine Institute; SIICT: Seasonal Influenza Immunization Costing Tool; WHO: World Health Organization.

Table A2b shows the characteristics of costing tools¹ that have been developed for costing vaccine delivery or immunization programmes that were identified by the Working Group. It includes five tools for costing the introduction of single antigens, three to estimate immunization programme costs, one for estimating the cost-effectiveness of introducing

a new vaccine or vaccine technology, one for estimating vaccine technology costs and health impact, and one for estimating costs of vaccination in the second year of life. Characteristics were self-reported by the tool developers in the Working Group.

Table A2b. List of costing tools for vaccine delivery or immunization programme

| | Delivery modality | Antigens included | Retrospective vs. prospective data collection | Retrospective vs. projection analysis | Full or incremental costs | Economic vs. financial (or unde- preciated financial) | Intended perspective | Intended data sources | Sampling | Intended use of results |
|------------------|--|-------------------------|---|---------------------------------------|---------------------------|---|---|---|-------------|-----------------------------|
| WHO C4P | Health facilitySchoolMultiple | HPV | - Retrospective | – Retrospective – Projection | Incremental | EconomicFinancialInitial investment | GovernmentProviderPayer | InterviewsFinancial recordsExpert opinion | No guidance | - Planning - RM - CEA |
| IVI CHOLTOOL | – SIA/campaign | Oral Cholera Vaccine | - Retrospective | - Retrospective - Projection | Incremental | – Economic – Financial | - Government - Payer | InterviewsFinancial recordsExpert opinion | No guidance | – Planning – RM – CEA |
| WHO SIICT | Health facilitySIA/campaignOutreachMultiple | Influenza | - Retrospective | – Retrospective – Projection | Incremental | – Economic – Financial | GovernmentProviderPayer | - Interviews - Financial records - Expert opinion | No guidance | – Planning – RM – CEA |
| WHO/IVI TCVCT | Health facilitySIA/campaignOutreachMultiple | Typhoid Conjugate | - Retrospective | – Retrospective – Projection | Incremental | – Economic – Financial | GovernmentProviderPayer | InterviewsFinancial recordsExpert opinion | No guidance | – Planning – RM – CEA |
| PATH MVICT | – Health Facility – Outreach | RTS,S | - Retrospective | - Retrospective - Projection | Incremental | EconomicFinancialInitial investment | - Government - Provider | InterviewsFinancial recordsExpert opinion | No guidance | – Planning – RM – CEA |

¹ Costing tools perform analyses and some have accompanying data forms such as the IVI CHOLTOOL.

| | Delivery modality | Antigens included | Retrospective vs. prospective data collection | Retrospective vs. projection analysis | Full or incremental costs | Economic vs. financial (or unde- preciated financial) | Intended perspective | Intended data sources | Sampling | Intended use of results |
|-------------------------|--|----------------------|---|---------------------------------------|---------------------------|---|---|---|--|---|
| WHO cMYP | Health facilitySIA/campaignOutreachMultiple | All | - Retrospective | - Retrospective - Projection | Full | – Undepreciated financial | – Government | InterviewsFinancial recordsExpert opinion | No guidance | – Planning – RM |
| UN OneHealth Tool | - Health Facility - Outreach - Multiple | All | - Retrospective - Prospective | – Projection | Incremental or full | – Financial | - Government | InterviewsFinancial recordsExpert opinion | No guidance | PlanningBudgetingRMCEA |
| PAHO ProVac/ Costvac | – Health Facility – Outreach | All | - Retrospective | - Retrospective | Full | - TBD | GovernmentProviderPayer | InterviewsFinancial recordsExpert opinion | RandomselectionConvenience | - Budgeting - Efficiency |
| PAHO ProVac/ UNIVAC | – Health Facility – Outreach | All | – Retrospective | - Retrospective | Full | - TBD | GovernmentProviderPayer | InterviewsFinancial recordsExpert opinion | RandomselectionConvenience | – Budgeting – CEA |
| PATH VTIA | – Health Facility – Outreach | All | – Retrospective | – Projection | Incremental | – Economic | NA | InterviewsFinancial recordsExpert opinion | Convenience | PlanningDecision- making |
| UNICEF 2YL | – Health Facility | All | - Retrospective | – Projection | Incremental | – Economic – Financial | - Health sector - Government | InterviewsFinancial recordsExpert opinion | No guidance | – Planning |

2YL: Tool for estimating costs of implementing a second year of life healthy child visit; C4P: Cervical Cancer Prevention and Control Costing; CEA: cost-effectiveness analysis; CHOLTool: Oral Cholera Vaccine Costing Tool; cMYP: Immunization costing & financing: a tool and user guide for comprehensive multi-year planning; HPV: human papillomavirus; IVI: International Vaccine Institute; MVICT: Malaria Vaccine Immunization Costing Tool; RM: resource mobilization; SIA: supplemental immunization activity; SIICT: Seasonal Influenza Immunization Costing Tool; TCVCT: Typhoid Conjugate Vaccine Costing Tool; UN: United Nations; UNICEF: United Nations Children's Fund; VTIA: Vaccine Technology Impact Assessment Tool; WHO: World Health Organization.

Annex 3. Definition of costing terminology

Table A3 shows the definition of costing terms presented in the various guidance documents. Most of the guidance documents have similar definitions of financial and economic costs, capital costs, and incremental costs but differ in the level of detail in their explanations. Fewer documents (less than three) have definitions of cost projections, prospective and retrospective costing, perspective, and bottom-up and top-down costing. The GHCC guidance document has the most definitions while other guidance documents focused on methods.

Other differences among the guidance documents are variations in definitions of vaccine delivery cost and prospective costing. The EPIC and ICAN definition of vaccine delivery are that it includes costs of delivering vaccines, exclusive of vaccines. The costing tools, however, use the term service delivery for operational costs of delivering vaccines, exclusive of vaccines, while "vaccine delivery cost" includes all the value of all resources involved in the immunizations. Prospective costing is defined as "direct observation" in EPIC and as projection of costs in the costing tools.

Table A3. Definitions of costing terms in guidance documents

| | WHO 1994 ^a | WHO 2002 ^b | ICAN (Methodology summary ^c) & EPIC ("How to Cost Immunization Programms" ^d and "Common Approach" ^e) | GHCCf | Costing tools' user manuals (C4P ^g , SIICT ^h , CHOLTOOL ⁱ) | cMYP guideline ^j | Recommendation |
|-----------------------|-----------------------|-----------------------|--|-------|---|-----------------------------|---|
| Vaccine delivery cost | NA | NA | Costs associated with delivering immunizations to target populations, exclusive of vaccine costs (p.11 °c) All resources used, whether immunization-specific, or "shared, and whether consumed at immunization delivery "sites" or above the level of service delivery, with and without the new vaccine (p. 5 °d) | NA | Vaccine delivery includes start-up costs, service delivery (personnel time, supplies and transport/allowance), vaccine procurement, monitoring and supervision, and other costs (p. 2629) | NA | Use ICAN/ EPIC definition, specify whether is inclusive or exclusive of vaccines and that includes recurrent and capital costs |

| | WHO 1994 ^a | WHO 2002 ^b | ICAN (Methodology summary ^c) & EPIC ("How to Cost Immunization Programms" ^d and "Common Approach" ^e) | GHCCf | Costing tools' user manuals (C4P ^g , SIICT ^h , CHOLTOOL ⁱ) | cMYP guideline ^j | Recommendation |
|--|--|--|--|--|---|-----------------------------|---|
| Financial cost | NA | Actual expenditure for resources used for goods or services purchased; does not include cost of existing health personnel time or donated goods (p. 2) | Financial outlays, usually with straight-line depreciation of capital items (p. 31°) A financial costing is concerned with accounting transactions (i.e., monetary outlays or expenditures) (p. 7°) | Capture the resources that are "paid" for (p. A-8) | Actual monetary flows of the buyer such as the Ministry of Health; does not include the value of resources already paid for, such as personnel time (p. 21 h) | NA | Composite of three definitions, noting that perspective affects the specification of the ingredients |
| Economic cost | Value of resources used to produce something, including a specific health service or a set of services (p. 13) | Resources that have been foregone for alternative uses, or opportunity costs (p. 2) | Financial outlays plus opportunity costs such as health worker time and any donated items such as vaccines (p. 56°) An economic costing values resources based on their opportunity cost, regardless of whether a financial transaction occurred (p. 7°) A valuation of all inputs needed for the routine immunization programme including valuation of time, supplies, equipment, and annualization of costs that adjusts for a discount rate (p. 6°) | The value of the highest alternative health intervention opportunity forgone; captures the full value forgone of all resources used (p. A-8) | Estimates all costs of an intervention, regardless of the source of funding, so that the opportunity cost of all resources is accounted for in the analysis, includes in-kind and donor contributions (p. 21 ^h) | NA | ICAN/EPIC definition, with clarification that includes resources from all payers/ resource providers |
| Undepreciated financial cost (called initial investment in costing tool guides and referred to as fiscal costs in previous analyses) | NA | NA | Financial outlays, usually without depreciation of capital items (p. 31°) | NA | Initial upfront resource requirements (p. 268°) | NA | ICAN/EPIC definition |

| | WHO 1994 ^a | WHO 2002 ^b | ICAN (Methodology summary ^c) & EPIC ("How to Cost Immunization Programms" ^d and "Common Approach" ^e) | GHCC ^f | Costing tools' user manuals (C4P ⁹ , SIICT ^h , CHOLTOOL ⁱ) | cMYP guideline ^j | Recommendation |
|---|--|--|---|--|--|---|---|
| Start-up or introduction costs | NA | NA | All resources used for one-time activities (e.g., social mobilization, cold chain capacity mobilization expansion) in a defined time period around the introduction (p. 4 ^d) Costs that are incremental to the routine immunization system and specifically incurred as a result of introduction of the new vaccine (p.17 ^e) | NA | Initial one-time programmatic activities and include microplanning, initial training activities, and initial sensitization/social mobilization/information, education and communication (p. 21h) | NA | Costing tool user manual definition, with clarification on difference between initial and continuing activities |
| Recurrent cost | NA | Items that are used up during a year (p. 3) | Recurrent items include labor and consumable items such as vaccines doses, supplies and travel costs (p. 11 d) | Value of resources/ inputs with useful lives of less than one year (p. 61) | Goods or items used in the delivery of a service or intervention that last less than a year, e.g., personnel salaries (p. 21h) | Costs of resources consumed within one year (p. 19) | Composite definition |
| Capital cost (sometimes called investment cost) | Inputs that last for more than one year (p. 6) | Items that last longer than one year and are therefore incurred only every few years rather than annually (p. 3) | Capital items are durable items such as building, equipment, and vehicles (p. 11 d) | One-time costs for items that have a useful life of over one year (p. B-23) | Goods that last for longer than one year, such as equipment (p. 21 ^h) | An input that has a useful life of more than one year (p. 19) | Composite definition |
| Incremental cost | NA | Only looks at the cost of an addition, e.g., a new vaccine, to existing services (p. 2) | Additional costs associated with introducing new vaccines or making changes in delivery (p. 32°) Make assumptions about what particular resources were affected by the intervention, and only measure those resources (p. 8 ^d) | Cost of adding a new or a batch of services or intervention over and above an existing programme (p. 59) | Additional resources required to add an intervention to an existing immunization programme (p. 6 ⁱ) | NA | Composite of definitions, with clarification that if resources are not slack, then have to account of opportunity cost |

| | WHO 1994 ^a | WHO 2002 ^b | ICAN (Methodology summary ^c) & EPIC ("How to Cost Immunization Programms" ^d and "Common Approach" ^e) | GHCC ^f | Costing tools' user manuals (C4P g, SIICT h, CHOLTOOL i) | | Recommendation |
|--------------------------------------|-----------------------|-----------------------|---|---|--|---|--|
| Full cost | NA | NA | The sum of all costs associated with vaccination delivery (p. 31°) Full costs include baseline cost as well as the additional cost of the new intervention (p. 8 ^d) | NA | NA | NA | ICAN/EPIC defi- nition, with clarifi- cation that includes vaccines and basic infrastructure |
| Prospective | NA | NA | Direct observation (p. 21 ^d) | Direct observation of resource use (p. B-18) | NA | NA | Composite of definitions, with clarification that costs are collected concurrently with interventions implementation |
| Retrospective | NA | NA | NA | Data collection takes place after resource use (p. B-18) | NA | NA | GHCC definition |
| Cost projection | NA | NA | NA | NA | NA | Total future costs of both recurrent and capital inputs to the national immunization programme (p. 108) | cMYP definition with clarification that is for intervention or programme |
| Micro-costing/ ingredient costing | NA | NA | Approach in which prices and quantities of resources are measured (p. 4 ^d) | Focuses on granular accounting of inputs; disaggregates costs of particular output into specific items consumed (p. A-13) | | NA | GHCC definition |

| | WHO 1994 ^a | WHO 2002 ^b | ICAN (Methodology summary ^c) & EPIC ("How to Cost Immunization Programms" ^d and "Common Approach" ^e) | GHCCf Costing tools' user manuals (C4P g, SIICTh, CHOLTOOLi) | | cMYP guideline ^j | Recommendation |
|---------------------------------------|-----------------------|-----------------------|--|--|----|-----------------------------|-------------------------|
| Bottom-up costing vs top-down costing | NA | NA | NA | Bottom-up measures input quantities at the client or activity level; top-down divides overall programme cost or expenditures, often including those above service level, by number of outputs to calculate unit cost (p. A-13) | NA | NA | GHCC definition |
| Perspective | NA | NA | The point of view considered for costs (and benefits, if included), in a costing study; to whom the costs were incurred; common perspectives include provider, government, healthcare, insurer and societal (p. 32°) Perspective has to do with which costs we care about; a study from the "societal" perspective should include all costs, no matter who in society pays them; the more commonly used "health sector" perspective is narrower (p. 7d) | Describes which payers' costs are included in the estimate, for example, a provider perspective may include costs incurred by health service providers, non-health service providers, and be limited to specific payers (p. B-2) | NA | NA | Composite definition |

^a WHO Cost analysis in primary health care: a training manual for programme managers

^b WHO Guidelines for estimating costs of introducing new vaccines into the national immunization system

^c ICAN Methodology summary

^d EPIC How to cost immunization programs: a practical guide on primary data collection and analysis

e EPIC Common approach for the costing and financing analyses of routine immunization and new vaccine introduction costs

^f GHCC Reference case for estimating the costs of global health services and interventions

g WHO Cervical Cancer Prevention and Control Costing (C4P) Tool: screening and treatment module user manual

^h WHO Seasonal Influenza Immunization Costing Tool (SIICT) user manual

ⁱ IVI/WHO Oral Cholera Vaccine Costing Tool (CHOLTOOL)

^j WHO Immunization costing & financing: a tool and user guide for comprehensive multi-year planning (cMYP)

In addition, most guidance documents define incremental costing but not full costing. Only one of the documents (EPIC) had nuanced discussions of how perspective affects financial costs, incremental costing affects economic costs, and how the purpose of the analysis affects what cost ingredients should be included. Specifically, the perspective of the costing affects the designation of which inputs/resources donated, e.g., vaccines in Gavi-eligible countries are donated if the perspective is the government and therefore would appear only as an economic cost, whereas if the study were conducted from a health sector perspective, these might be included as financial costs. It is critical to clarify if the perspective is defined in terms of the payer (i.e., the organization outlaying the funds

directly to the provider of goods or services) or the funding source; for example, when donor funds are channeled to the government and the government conducts the monetary outlay, this would be considered both an economic cost if the government perspective is used but financial and economic costs if defined in terms of the payer (donor). Thus, the perspective will affect which resources are included in financial costs. For incremental costs, the guidance documents define these as additional costs incurred with the introduction of a new vaccine or other technology but don't indicate what inputs/resources should be included in economic costs, i.e., which recurrent and existing capital costs should be included.

Annex 4.

Costing principles

Table A4 compares the costing principles in the guidance documents with the GHCC Principles and Methods Reporting Checklist. The guidance documents focus on five of the principles:

- **1.** defining the purpose of the study (GHCC principle 1);
- classifying the costs as recurrent/capital and financial/economic (GHCC principle 3);
- **3.** specifying the time horizon of data collection (GHCC principle 5);
- **4.** presenting costing methods (GHCC principle 7);
- **5.** depreciating the capital costs (GHCC principle 12).

Other GHCC principles were only discussed in one or two of the other guidance documents:

- **1.** importance of stating the perspective (GHCC principle 2);
- **2.** scope of costing (GHCC principles 5 and 6);
- **3.** sampling strategy (GHCC principle 8);
- **4.** timing of data collection (GHCC principle 10);
- **5.** sources for price data (GHCC principle 11);
- **6.** selection of discount rate (GHCC principle 13);
- **7.** use of shadow prices (GHCC principle 14);
- **8.** characterization of uncertainty (GHCC principle 16).

The recommended costing principles are also found in Section 5 of the guidance.

Table A4. Comparison of costing principles among guidance documents

| GHCC Principle | WHO 1994 | EPIC/Common Approach/ Reference Guide | Costing Tools | сМҮР | Recommendation in the guidance (Section 5) |
|--|--|--|--|--|---|
| The purpose, the population, and the intervention and/or service/output of the cost estimation should be clearly defined | NA | At the earliest stage of planning a costing exercise, one should consider objectives and rationale | User should assess whether financial or economic costs are most appropriate based on the objective (C4P, SIICT, CHOLTOOL, SIICT, TCV, MVICT) | The objectives are to analyze programme costs, financing and financing gaps and these should be linked to the programme objectives | Combined GHCC principles 1 and 5 (Principle # 2): The study scope in terms of its purpose, audience, target population, time horizon, and service/output should be clearly stated. It should also state whether data collection will be prospective or retrospective, and whether the analysis will be retrospective or a cost projection. |
| The perspective of the cost estimation should be stated and justified | NA | Perspective is an important concept that is somewhat unique to economic studies, as compared to other types of health service research | NA | NA | Applied GHCC principle (Principle # 3): The perspective of the cost estimation should be stated and justified. |
| The type of cost should be clearly defined, in terms of economic vs. financial, incremental vs full cost, and whether the cost is "net of future cost" | Costs should be classified by inputs (recurrent and capital); can also be classified by function/ activity, level, source, and type of currency Economic costing should be used for cost- effectiveness analyses | It is important to make the distinction between financial and economic costs | Costs are classified as financial and economic as well as recurrent and capital in the costing tools (C4P, SIICT, CHOLTOOL, TCV, MVICT) | Costs are defined as recurrent and capital | Composite of definitions (Principle # 4): Types of costs to be generated should be clearly defined in terms of start-up/ introduction or non- start-up/introduction, recurrent and capital, undepreciated financial, financial or economic, and incremental or full. Capital costs should be appropriately annualized and depreciated for financial and economic costs and the discount rate justified. |
| 4 The "units" in the unit costs for strategies, services and interventions should be defined | Explains general nature of unit costs and gives examples of unit costs | All resources used in an intervention divided by number of vaccination | Unit costs are measured as cost per dose administered, child or girl fully vaccinated | NA | Composite of definitions (Principle # 6): The "units" in the unit costs for strategies, services and interventions should be defined, e.g., cost per dose administered. |

| GHCC Principle | WHO 1994 | EPIC/Common Approach/ Reference Guide | Costing Tools | сМҮР | Recommendation in the guidance (Section 5) |
|--|---|--|--|--|---|
| The time horizon of data collection should be explicit and of sufficient length to capture costs relevant to the purpose, and consideration should be given to disaggregating costs into separate time periods where they vary over time | Should choose the most recent year for which cost data are available for one full year | When collecting primary data retrospectively, one must set boundaries of the time horizon in which resource use occurred | The user should specify whether the estimates are cost projection or retrospective analyses (C4P, CHOLTOOL, MVICT) | Planning horizon is five years or less | Combined GHCC principles 1 and 5 (Principle # 2) |
| The scope of the inputs to include in the cost estimation should be defined and justified relevant to purpose | Need to be clear about scope of the costing | The decisions about scope should be made when planning the exercise, before data is collected | NA | NA | Composite of definitions (Principle # 5): The scope of the inputs to be estimated should be defined, justified and if needed referenced. For example, do the costs include national and sub-national costs or only facility service delivery costs? Are non-immunization costs included? |
| The methods for estimating the quantity of inputs should be described, including methods, data sources and criteria for allocating resources | NA | Presents methods for recurrent and capital costs | Presents methods of calculation and suggests data sources (C4P, SIICT, CHOLTOOL, TCV, MVICT) | Ingredients approach is used to estimate costs – quantities × price × % used in immunization | Composite of definitions (Principle # 9): The methods for estimating the quantity of inputs should be described – whether top-down or bottom- up, methods of allocation, use of shadow prices and opportunity cost of time, and methods for excluding research and evaluation costs. |
| 8 The sampling strategy used should be specified and designed to minimize bias | It is necessary to choose a sample and use one of four types: either random, cluster, systematic, or stratified | Published guidance for sampling health facilities that was developed for health facility data collection alongside Demographic and Health Surveys can be applied to immunization costing studies | NA | NA | Combined definitions and edits by Working Group (Principle # 12): The sampling strategy employed should aim for internal and external validity of the data. Sampling strategy should be stated, described, and justified, depending on the workstream and costing objectives. Sampling of different service delivery units is desirable as it provides a more representative picture of costs and highlights cost variation and cost drivers for a strategy or vaccine. |
| The selection of the data source(s) and methods for estimating service use should be described, and potential biases reported in the study limitations | Methods are described | Recommend being aware of the quality of available data sources and reporting systems and comparing data sources | Data sources and methods for estimating service use are described (C4P, SIICT, CHOLTOOL, TCV, MVICT) | NA | Composite of definitions (Principle # 8): The selection of the data sources, including any adjustments to price data (e.g., inflation or currency conversion) should be described and referenced. |

| GHCC Principle | WHO 1994 | EPIC/Common Approach/ Reference Guide | Costing Tools | сМҮР | Recommendation in the guidance (Section 5) |
|---|---------------------------------------|--|---|------|--|
| Consideration should be given to the timing of data collection to minimize recall bias and, where relevant, the impact of seasonality and other differences | NA | Notes that the major advantage of direct observation methods is lack of recall bias | NA | NA | Not included |
| The sources for price data should be listed by input, and clear delineation should be made between local and international price data sources, and tradeable, non-tradeable goods | NA | The "Common Approach" lists the sources of information for unit vaccine prices; the "How to Cost Immunization Programs" lists sources of data for prices | Sources for price data should be noted in the designated worksheets (C4P, SIICT, CHOLTOOL, TCV, MVICT) | NA | Included in Principles # 8 and 9 |
| Capital costs should be appropriately annuitized or depreciated to reflect the expected life of capital inputs | Recommends straight line depreciation | For economic cost evaluation, all capital costs need to be annualized based on a discount rate and estimates of useful life | Straight line depreciation is calculated for financial costs, and annualization and discounting for economic costs (C4P, SIICT, TCV, MVICT) | NA | Included in Principle # 4 |
| 13 Where relevant, an appropriate discount rate, inflation and exchange rates should be used, and clearly stated | NA | Recommends using a 3% discount rate unless there is another justification | NA | NA | Included in Principle # 4 |
| 14 The use and source of shadow prices for goods and the opportunity cost of time should be reported | NA | NA | NA | NA | Included in Principle # 9 |

| GHCC Principle | WHO 1994 | EPIC/Common Approach/ Reference Guide | Costing Tools | сМҮР | Recommendation in the guidance (Section 5) |
|---|----------|--|---------------|---|--|
| Variation in the cost of the intervention by site/organization, sub-populations, or by other drivers of heterogeneity should be explored and reported | NA | One of the main questions of the "Common Approach" is to assess the factors that drive the variation between facility total and unit costs; EPIC has an analytical tool and database to facilitate comparisons across facilities | NA | NA | Included in Principle # 13 |
| The uncertainty associated with cost estimates should be appropriately characterized | NA | Standard statistical approaches can be used to calculate an unbiased measure of mean, and the uncertainty in this mean estimated | NA | Recommends scenario- building to take in account uncertainty; also risk assessment | Combined two principles in Principle # 14: The uncertainty around the cost estimates should be appropriately characterized, e.g., sensitivity analyses, ranges of results for different input parameter scenarios for cost projections, mean and standard deviation for non-representative samples with multiple units, and confidence intervals or credible intervals for retrospective analyses. |
| Cost estimates should be communicated clearly and transparently to enable decision-maker(s) to interpret and use the results | NA | Section in the "Common Approach" focuses on writing up results | NA | It is essential to communicate the results clearly | Combined two principles in Principle # 16: Cost estimates should be communicated clearly and transparently to enable decision-makers to interpret and use the results relevant to the original policy and/or programmatic question. |

Annex 5.

Characteristics of costing workstreams

Table A5a shows characteristics of the four costing workstreams identified based on recent work known to the Working Group. It shows that the activities/cost categories used in costing are largely similar within the guidance documents for immunization costing. However, in a few cases, the terminology differs, e.g., vaccines/injection supplies for programme costing, vaccine procurement for cost projections and retrospective campaign costing, and vaccine, collection, distribution and storage for retrospective routine immunization costing. In addition, some workstreams

use the term service delivery to encompass health personnel time, supplies, and transport while other workstreams separate these into individual components. Also, two of the workstreams, programme costing and retrospective routine costing, explicitly mention surveillance as an activity while the other workstreams include surveillance under the monitoring activity/cost category. Similarly, two of the workstreams include micro-planning, cost projections and retrospective campaign costing, while this activity is not included in the other workstreams.

Table A5a. Characteristics of costing workstreams

| | Level of data collection | Activities/cost categories | Perspective | Incremental or full cost | Similarities and differences in workstream guidance in definitions of terms and perspective |
|--|---|--|---------------------------------|--------------------------|---|
| Retrospective routine immunization cross-sectional coststing | Facility with some data collection at higher levels | Vaccine (procurement), collection, distribution, storage Facility-based service delivery (personnel time and resources) Monitoring and evaluation Supervision Training Social mobilization Surveillance Programme management Cold chain maintenance Other capital goods | Provider, payer, or societal | Full or incremental | Similar definitions of financial and economic costs and recurrent and capital costs Uses health sector perspective |

| | Level of data collection | Activities/cost categories | Perspective | Incremental or full cost | Similarities and differences in workstream guidance in definitions of terms and perspective |
|--|--|--|---|--------------------------|---|
| Retrospective single- vaccine costing | Programme and facility with sampling or interviews with programme managers | Vaccine procurement Service delivery (personnel and transport) Distribution Supervision Micro-planning Training Other recurrent activities Cold chain equipment AEFI surveillance Other capital goods | Provider, payer, or societal | Incremental | Similar definitions of financial and economic costs and recurrent and capital costs Uses government and payer perspectives Costing tools assume incremental economic costs do not include existing equipment since these have available capacity (excess capacity) |
| Projection of new vaccine introduction costs | Programme and facility | Vaccine procurement Service delivery (personnel and transport) Distribution Supervision Micro-planning Training Other recurrent activities Cold chain equipment AEFI surveillance Other capital goods | Provider, payer, or societal | Incremental | Similar definitions of financial and economic costs and recurrent and capital costs Uses government and payer perspectives Assumes incremental economic costs do not include existing equipment since these have available capacity (excess capacity) |
| Projection of immunization programme costs | Programme | Vaccines/injection supplies Personnel Transport Social mobilization/IEC Training Supervision Monitoring (includes surveillance) Cold chain equipment Other capital goods | Provider (could include external funding) | Full or incremental | Similar definitions of recurrent and capital costs except for US\$100 requirement for capital costs per item; uses straight line depreciation Cost projections also similar to other definitions Perspective is government but includes value of donated goods and personnel time |

AEFI: adverse event following immunization; IEC: information, education and communication.

Variation among workstreams

The workstreams shows the different approaches on data sources, sampling, and characterization of uncertainty, as shown in Table A5b. This makes sense given the different recommended uses of the different workstreams. For example, cost projections of new vaccine introduction or a five-year immunization programme are by definition an exercise in assumptions about an unknown future programme with hypothetical

information on costs and quantities; therefore, larger or more representative sampling of sites may not reduce uncertainty about this future programme, whereas exploration of a range of scenario input parameters can help identify influential programmatic and cost elements and the range of possible cost results.

Table A5b. Data sources, sampling and characterization of uncertainty, and terminology by workstreams

| | Recommended use | Perspective | Data sources | Sampling | Characterizing uncertainty |
|--|---|---------------------------------|---|---|--|
| Retrospective routine immunization cross-sectional costing | Compare costs of vaccine delivery for benchmarking and to explain variation in facility costs and unit costs and evaluate efficiency and equity | Provider, payer, or societal | Health facility records; interviews with national and sub-national programme managers | Representative sampling of health facilities (stratified, random) | Characterized based on number of sites in sample, stratification of units, and basis of probability of selection; one-way sensitivity testing or scenario analysis |
| Retrospective single- vaccine ccosting | Estimate costs of campaigns or routine health facility delivery for benchmarking and to explain variations by strategy and venue | Provider, payer, or societal | Interviews with national and sub- national programme managers | Representative sampling of health facilities or campaign sites; Convenience samples | Characterized based on number of sites in sample, stratification of units, and basis of probability of selection |
| Projection of new vaccine introduction costing | Estimate costs to assist programme managers in planning and decision-making on vaccine introduction | Provider, payer, or societal | No guidance provided; practice is to use expert opinion; conduct visits to selected health facilities; and hold workshops with stakeholders | No guidance provided | Costing tools are not specific but suggest use of scenarios |
| Projection of Immunization programme costing | Estimate costs to assist in budgeting, planning and resource mobilization over a five-year period | Provider | Interviews with national and sub- national programme managers; visits to selected health facilities sometimes | Can collect data at the sub- national as well as national levels | Conduct scenario analysis to have a range of estimates |

Annex 6.

Areas for clarification and harmonization

Areas for clarification and harmonization are defined as problem areas or areas without a consensus. The following are the areas that have been identified from the review of guidance documents and costing tool manuals.

- Definitions on terminology among and within workstreams differ and need to be harmonized, where appropriate, acknowledging the different workstream purposes. See Section 5 of the guidance for recommended terms.
- **2.** The options for study perspective should be agreed upon by Working Group, including use of perspective in financial vs. economic costing.
- **3.** Inconsistent labeling of programme activities vs. resource inputs as cost categories, inconsistent nesting of resource inputs inside programme activities and vice versa without regard for the perspective of the analysis.

- **4.** Definition of incremental and full costing is not consistent.
- **5.** Sampling and uncertainty: What are the appropriate sampling approaches (random or purposive) for different costing objectives (assuming time and money are not the limitations)? What level of uncertainty is appropriate?
- **6.** Gaps in practical guidance on aggregating costs across levels of the health system and clarity on level of activity vs. level of payer.

